Correction to: Adverse effects associated with regadenoson myocardial perfusion imaging

Efstathia Andrikopoulou, MD,^a and Fadi G. Hage, MD, FASNC, FACC^{b,c}

^a Sub-division of Non-Invasive Cardiovascular Imaging, Division of Cardiovascular Disease, Department of Medicine, Brigham and Women's Hospital, Boston, MA

^b Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

^c Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL

doi:10.1007/s12350-018-1281-0

CORRECTION TO: J NUCL CARDIOL

[HTTPS://DOI.ORG/10.1007/S12350-018-1218-7](https://doi.org/10.1007/s12350-018-1218-7)

Near the beginning of the first sentence in the second paragraph of the Introduction the parenthetical

phrase should read: (single bolus of 400 mcg given intravenously, IV). The dosage of mcg was incorrectly published as 200 mcg.

The original article can be found online at <https://doi.org/10.1007/s12350-018-1218-7>.

Reprint requests: Efstathia Andrikopoulou, MD, Sub-division of Non-Invasive Cardiovascular Imaging, Division of Cardiovascular Disease, Department of Medicine, Brigham and Women's Hospital, 75 Francis street, ABI L1-027, Boston, MA 02115; eandrikopoulou@bwh.harvard.edu

J Nucl Cardiol 2018;25:1732.

1071-3581/\$34.00

Copyright © 2018 American Society of Nuclear Cardiology.